These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 23412117)

  • 1. [A case of complete response of multiple lung metastases of renal cell carcinoma with the flexible administration of sunitinib].
    Kim H; Shoji S; Usui Y; Nagata Y; Terachi T; Uchida T
    Hinyokika Kiyo; 2013 Jan; 59(1):7-10. PubMed ID: 23412117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Brain metastasis which appeared during complete response of lung metastatic lesion by sunitinib treatment in a patient with renal cell carcinoma].
    Morizawa Y; Momose H; Toyoshima Y; Takada S; Fujimoto K; Oyama N
    Hinyokika Kiyo; 2013 Dec; 59(12):791-3. PubMed ID: 24419011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A case of interstitial lung disease due to sunitinib].
    Sekiguchi Z; Takizawa A; Takeshima T; Tsuchiya F; Iwasaki A; Matsuyama S; Hirooka N
    Hinyokika Kiyo; 2012 Sep; 58(9):481-5. PubMed ID: 23070386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of Sunitinib Rechallenge in Metastatic Renal Cell Carcinoma : A Case Report].
    Yoshinaga A; Kamata S
    Hinyokika Kiyo; 2015 May; 61(5):201-5. PubMed ID: 26087822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [PATHOLOGICAL COMPLETE RESPONSE WITH EVEROLIMUS FOR MULTIPLE LUNG METASTASES OF RENAL CELL CARCINOMA RESISTANT TO SUNITINIB].
    Namura K; Otake S; Sawada T; Fujikawa A; Ota J; Moriyama M
    Nihon Hinyokika Gakkai Zasshi; 2015 Jan; 106(1):30-4. PubMed ID: 26399128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Metastasis to the Tongue from Renal Cell Carcinoma 10 Years after Nephrectomy : A Case Report].
    Wang C; Takeda K; Shiba M; Takayama H; Munakata S
    Hinyokika Kiyo; 2016 Aug; 62(8):407-10. PubMed ID: 27624106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial.
    Sternberg CN; Calabrò F; Bracarda S; Cartenì G; Lo Re G; Ruggeri EM; Basso U; Gasparini G; Ciuffreda L; Ferrari V; Bonetti A; Fea E; Gasparro D; Tassinari D; Labianca R; Masini C; Fly K; Zhang K; Hariharan S; Capaccetti B; Porta C
    Oncology; 2015; 88(5):273-80. PubMed ID: 25592399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of a low-dose, 2-week administration of sunitinib followed by a week rest (2/1 schedule) for metastatic renal cell carcinoma: a single center experience of six cases.
    Makino K; Yoda K; Tomoishi J; Kume H
    BMC Res Notes; 2014 Dec; 7():872. PubMed ID: 25471941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of efficacy and safety of sunitinib regimen in 22 patients with metastatic renal cell carcinoma: at least 12-month follow-up.
    Zhang CJ; Zhao PJ; Li XS; Zhao J; Huang LH; Song Y; Gong K; Shen C; Yu W; Song G; Zhao Z; Zhang Z; Zhang Q; He ZS; Jin J; Zhou LQ
    Chin Med J (Engl); 2013; 126(15):2826-9. PubMed ID: 23924450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of traditional and alternative sunitinib treatment schedules in Japanese patients with metastatic renal cell carcinoma.
    Ohzeki T; Fukasawa S; Komaru A; Namekawa T; Sato Y; Takagi K; Kobayashi M; Uemura H; Ichikawa T; Ueda T
    Int J Urol; 2014 Oct; 21(10):1065-8. PubMed ID: 24930736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal cell carcinoma: complete response.
    Calvo OF; Vázquez DD; López MR; Aparicio LM
    Anticancer Drugs; 2010 Jan; 21 Suppl 1():S17-8. PubMed ID: 20110782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pre- surgical therapy with sunitinib for adrenal metastasis from renal cell carcinoma : a case report].
    Inoue T; Murota T; Masuda T; Nishida T; Kawakita S; Kinoshita H; Matsuda T
    Hinyokika Kiyo; 2013 Sep; 59(9):573-7. PubMed ID: 24113755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous therapy with sunitinib in patients with metastatic renal cell carcinoma.
    Kahl C; Hilgendorf I; Freund M; Casper J
    Onkologie; 2008 Sep; 31(8-9):485. PubMed ID: 18787358
    [No Abstract]   [Full Text] [Related]  

  • 15. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
    Johannsen M; Flörcken A; Bex A; Roigas J; Cosentino M; Ficarra V; Kloeters C; Rief M; Rogalla P; Miller K; Grünwald V
    Eur Urol; 2009 Jun; 55(6):1430-8. PubMed ID: 18950936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new modified schedule of sunitinib for metastatic renal cell carcinoma: a retrospective analysis.
    Buti S; Donini M; Lazzarelli S; Passalacqua R
    Acta Biomed; 2012 Aug; 83(2):88-94. PubMed ID: 23393915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma.
    Bracarda S; Negrier S; Casper J; Porta C; Schmidinger M; Larkin J; Gross Goupil M; Escudier B
    Expert Rev Anticancer Ther; 2017 Mar; 17(3):227-233. PubMed ID: 28044472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and tolerability of a sunitinib 3-week administration schedule in metastatic renal cell carcinoma patients: report of three cases.
    Neri B; Vannini A; Tassi R; Brugia M; Rangan S; Rediti M; Cerullo C
    Oncol Res; 2012; 20(5-6):259-64. PubMed ID: 23581233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous daily dosing of sunitinib in patients with metastatic renal cell cancer.
    Harshman L; Srinivas S
    Onkologie; 2008 Sep; 31(8-9):432-3. PubMed ID: 18787349
    [No Abstract]   [Full Text] [Related]  

  • 20. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma.
    Thomas AA; Rini BI; Lane BR; Garcia J; Dreicer R; Klein EA; Novick AC; Campbell SC
    J Urol; 2009 Feb; 181(2):518-23; discussion 523. PubMed ID: 19100579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.